drug · small molecule
zipalertinib
pre_registrationupdated 3mo agoby Taiho Pharmaceutical Co Ltd🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3, with 1 investigational indication.
indications
indications
NSCLC
targets
Epidermal growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying zipalertinib
- phase3A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- phase2Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
News(4)
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 21h ago
- Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionTaiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.biospace · 22h ago
- Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestTaiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…endpoints · 1d ago
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…fiercebiotech · 1d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that